Halozyme Therapeutics | HALO - Debt



Halozyme Therapeutics reported $1.51B in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
Acadia Pharmaceuticals USD 56.29M 56.29M Jun/2025
Agios Pharmaceuticals USD 48.76M 48.76M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amarin USD 0 0 Mar/2025
Amgen USD 56.2B 1.18B Jun/2025
Baxter International USD 10.31B 2.82B Mar/2025
Cytokinetics USD 658.13M 1.01M Mar/2025
DBV Technologies USD 8.29M 8.29M Jun/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Ionis Pharmaceuticals USD 1.42B 169.27M Jun/2025
MannKind USD 46.82M 243.3M Jun/2025
Pfizer USD 60.93B 1.18B Jun/2025
United Therapeutics USD 200M 100M Mar/2025